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Objective
We present a post hoc analysis from 3 phase III clinical
trials examining the effects of mometasone furoate/ formo-
terol (MF/F) combination therapy on asthma deterioration
(ie, severe asthma exacerbation) in subjects previously
uncontrolled on low-, medium-, or high-dose inhaled corti-
costeroids (ICS).
Methods
A2 –3-week run-in period with twice daily (BID) MF-
100µg, MF-200µg, or MF-400µg was performed before
subject (≥12y) randomization to BID: MF/F-100/10µg, MF-
100µg, F-10µg, or placebo for 26weeks (n=746); MF/F-200/
10mg, MF-200µg, F-10µg, or placebo for 26weeks (n=781);
MF/F-200/10µg, MF/F-400/10µg, or MF-400µg for
12weeks (n=728 ). Assessment of asthma deterioration (ie,
20% decrease in forced expiratory volume in 1s [FEV1];
30% decrease in peak expiratory flow [PEF] on ≥2 consecu-
tive days; or clinically judged deterioration [ie, emergency
treatment, hospitalization, or treatment with excluded
medications]) was a co-primary endpoint for studies, and a
secondary endpoint for study. Post hoc pair-wise compari-
sons of pooled MF/F vs MF, F, and placebo treatment
groups were performed.
Results
Sample sizes in this pooled analysis were: MF/F, n=861;
MF, n=620; F, n=390; placebo, n=384. There was a
significantly lower incidence of asthma deterioration with
MF/F= 17.2% vs MF=26.1% (P=.002), F=49.5% (P<.001),
and placebo550.8% (P<.001). Incidence rates for asthma
deterioration subtypes were: FEV1 reduction: MF/
F=7.0%, MF=10.0%, F=13.8%, placebo=17.7%; PEF reduc-
tion: MF/F=7.5%, MF=12.6%, F=27.2%, placebo=26.3%;
clinically judged deterioration: MF/F=2.1%, MF=2.6%,
F=6.7%, placebo=5.2%.
Conclusion
MF/F-treated subjects experienced a significantly lower
rate of asthma deterioration compared with MF, F, and
placebo in subjects previously uncontrolled on low-,
medium-, or high-dose ICS in this pooled analysis.
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